AIDS Therapies (PMPA)

Human Testing of Systemic PMPA for HIV Commenced

Published in AIDS Weekly, October 28th, 1996

Gilead Sciences, Inc., Foster City, California, announced the commencement of human clinical studies of PMPA.

In preclinical testing, PMPA has demonstrated potent activity against simian immunodeficiency virus (SIV) infection, a primate model for HIV. The Phase I/II randomized, double-blind, placebo-controlled human study is planned to assess the safety, tolerance, pharmacokinetics and anti-HIV activity of PMPA when administered by intravenous infusion to HIV infected patients.

The study was designed to enroll a total of 40 patients with CD4 cell counts greater than 200 cells/mm³ at the Johns Hopkins University School of Medicine,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry